Surrozen, Inc./DE Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Surrozen, Inc./DE (SRZN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $0 as of 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2024-04-10
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
- 2023-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $16.19M.
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $27.52M.
- 2022-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $34.64M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $16.19M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $27.52M 10-K · filed 2024-04-10 |
| 2022-09-30 | $34.64M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $37.14M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $40.83M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $34.37M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |